[1]Semenza GL. Regulation of tissue perfusion in mammals by hypoxia-inducible factor 1[J]. Exp Physiol,2007,92(6):988-991.[2]Loinard C,Ginouvès A,Vilar J,et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization[J]. Circulation,2009,120(1):50-59.
[3]Ho TK,Abraham DJ,Black CM,et al. Hypoxia-inducible factor 1 in lower limb ischemia[J]. Vascular,2006,14(6):321-327.
[4]Ivan M,Kondo K,Yang H,et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation:implications for O2 sensing[J]. Science,2001,292(5516):464-468.
[5]Lando D,Peet DJ,Whelan DA,et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch[J]. Science,2002,295(5556):858-861.
[6]Pei J,Wang Y,Liu C,et al. Effects of a triple mutant hypoxia-inducible factor-1alpha on proliferation and vascular endothelial growth factor expression in human microvascular endothelial cells[J]. Nan Fang Yi Ke Da Xue Xue Bao,2012,32(6):812-816.
[7]Li M,Liu C,Bin J,et al. Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle[J]. Microvasc Res,2011,81(1):26-33.
[8]Xie J,Liao Y,Yang L,et al. Ultrasound molecular imaging of angiogenesis induced by mutant forms of hypoxia-inducible factor-1alpha[J]. Cardiovasc Res,2011,92(2):256-266.
[9]卢庆威,王军,王刚,等. 基于数据库数据分析下肢动脉硬化闭塞症患者腔内介入术治疗后支架内再狭窄的危险因素[J]. 山东医药,2020,60(30):80-83.
[10]Miyata T,Mii S,Kumamaru H,et al. Risk prediction model for early outcomes of revascularization for chronic limb-threatening ischaemia[J]. Br J Surg,2021,108(8):941-950.
[11]Couffinhal T,Silver M,Zheng LP,et al. Mouse model of angiogenesis[J]. Am J Pathol,1998,152(6):1667-1679.
[12]Leong-Poi H,Christiansen J,Klibanov AL,et al. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins[J]. Circulation,2003,107(3):455-460.
[13]Schgoer W,Theurl M,Jeschke J,et al. Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism[J]. Circ Res,2009,105(10):994-1002.
[14]张迎春,刘永春. 下肢动脉硬化闭塞症治疗新进展[J]. 中国现代医药杂志,2019,21(2):103-105.
[15]吴庆华. 下肢动脉硬化闭塞症药物治疗及评价[J]. 中国实用外科杂志,2016,36(12):1256-1259.
[16]Inampudi C,Akintoye E,Ando T,et al. Angiogenesis in peripheral arterial disease[J]. Curr Opin Pharmacol,2018,39:60-67.
[17]Sanada F,Taniyama Y,Muratsu J,et al. Gene-therapeutic strategies targeting angiogenesis in peripheral artery disease[J]. Medicines (Basel),2018,5(2):31.
[18]Bosch-Marce M,Okuyama H,Wesley JB,et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia[J]. Circ Res,2007,101(12):1310-1318.
[19]Yu J,Dardik A. A murine model of hind limb ischemia to study angiogenesis and arteriogenesis[J]. Methods Mol Biol,2018,1717:135-143.
[20]Li X,Zhang Q,Nasser MI,et al. Oxygen homeostasis and cardiovascular disease:a role for HIF?[J]. Biomed Pharmacother,2020,128:110338.
[21]Heil M,Schaper W. Influence of mechanical,cellular,and molecular factors on collateral artery growth(arteriogenesis)[J]. Circ Res,2004,95(5):449-458.
[22]Scholz D,Ziegelhoeffer T,Helisch A,et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice[J]. J Mol Cell Cardiol,2002,34(7):775-787.
[23]Silvestre JS,Mallat Z,Tedgui A,et al. Post-ischaemic neovascularization and inflammation[J]. Cardiovasc Res,2008,78(2):242-249.
[24]Cramer T,Yamanishi Y,Clausen BE,et al. HIF-1alpha is essential for myeloid cell-mediated inflammation[J]. Cell,2003,112(5):645-657.